Targepeutics

Targepeutics is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight and diagnose cancer and other diseases. Our lead compound, GB-13, is currently advancing toward a Phase I clinical trial for several cancer targets. GB-13 is a genetically engineered recombinant protein that specifically binds and destroys cancer cells with minimal normal cell damage. We have also licensed related technology for a cancer immunotherapy that is in Phase III clinical trials.